City of Hope Selects Medidata Rave

National Cancer Institute-designated Comprehensive Cancer Center Standardizes on
EDC/CDM Solution to Support Phase I & II Cancer Studies
NEW YORK--(Business Wire)--
Medidata Solutions (NASDAQ: MDSO), a leading global provider of hosted clinical
development solutions, today announced City of Hope has selected Medidata Rave®
as its standard for electronic data capture (EDC) and clinical data management
(CDM) across its clinical trials. A leading biomedical research, treatment and
education institution for cancer, diabetes and other life-threatening diseases,
City of Hope plans to implement Medidata Rave for the management of Phase I and
II studies.

Based just outside Los Angeles, City of Hope is one of 40 National Cancer
Institute (NCI)-designated Comprehensive Cancer Centers, and a founding member
and the central Data Coordinating Center for the National Comprehensive Cancer
Network. Widely known for its innovation in oncology, numerous breakthrough
cancer drugs, including Herceptin, Rituxan, Avastin and Erbitux, are based on
technology pioneered by City of Hope. At any given time, City of Hope conducts
more than 300 clinical studies, including trials in support of its own
investigational new drugs in development, funded by industry or as part of a
multi-center cooperative group.

Under the leadership of Joyce Niland, Ph.D., chair of information sciences, City
of Hope was an early adopter of clinical trial technology and one of the first
cancer centers in the U.S. to develop its own electronic clinical information
system at a time when the majority of research organizations were still relying
on paper-based processes.

As part of City of Hope`s efforts to upgrade its clinical research technologies,
Gabriel Peterson, director of clinical research informatics, led the evaluation
of 10 EDC products. After an in-depth review, City of Hope`s team selected
Medidata Rave.

"Medidata Rave will enhance City of Hope`s capability for electronic data
capture by enabling more efficient execution of studies, near real-time data
capture to speed decision making and improved data quality through its query
management functionality," said Peterson.

In addition to providing a system with advanced features and functionality,
Medidata also demonstrated critical vendor stability and offered a range of
professional services. Working collaboratively with Medidata`s professional
services team, City of Hope trained eight of its core team members on Medidata
Rave in late 2009 and began building its own studies by early January 2010.
Within one week, the City of Hope team had built a significant portion of the
Medidata Rave functionality for its first pilot study and accelerated its
initial timelines for the roll out of its first Rave-based studies.

"City of Hope is driving some of the most critical cancer research in the
country, and we are very proud to have partnered with them to support those
efforts," said Tarek Sherif, Medidata Chairman and CEO. "City of Hope`s
selection of Medidata Rave not only speaks to its commitment to the industry`s
most cutting-edge and user-friendly technologies, but it also demonstrates our
ability to deliver clinical research solutions for sponsors and institutions
facilitating trials of all sizes, phases and categories."

About City of Hope

City of Hope is a leading research and treatment center for cancer, diabetes and
other life-threatening diseases. Designated as a Comprehensive Cancer Center,
the highest honor bestowed by the National Cancer Institute, and a founding
member of the National Comprehensive Cancer Network, City of Hope's research and
treatment protocols advance care throughout the nation. City of Hope is located
in Duarte, Calif., just northeast of Los Angeles, and is ranked as one of
"America`s Best Hospitals" in cancer and urology by U.S. News & World Report.
Founded in 1913, City of Hope is a pioneer in the fields of bone marrow
transplantation and genetics. For more information, visit www.cityofhope.org.

About Medidata Solutions Worldwide

Medidata Solutions (www.mdsol.com) is a leading global provider of hosted
clinical development solutions that enhance the efficiency of customers`
clinical development processes and optimize their research and development
investments. Medidata products and services allow customers to achieve clinical
results more efficiently and effectively by streamlining the design, planning
and management of key aspects of the clinical development process, including
protocol development (Medidata Designer®), investigator benchmarking and
budgeting (Medidata Grants Manager), contract research organization (CRO)
benchmarking and budgeting (Medidata CRO Contractor), and the capture,
management, analysis and reporting of clinical trial data (Medidata Rave®).
Medidata`s diverse customer base spans pharmaceutical, biotechnology and medical
device companies, academic institutions, CROs and other research organizations,
and includes more than 20 of the top 25 global pharmaceutical companies.

Lois Paul & Partners
Susan McCarron, 781-782-5767
Susan_McCarron@lpp.com

Copyright Business Wire 2010